MedTrace Logo

Feasibility of Integrating Homeopathic Approach in a Comprehensive Cancer Center

NCT05833165 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-08-07

No results posted yet for this study

Summary

Supportive and palliative care play an important role in cancer treatment, and when introduced early can improve quality of life and may even increase median survival rates, as shown in patients with advanced lung cancer. Complementary and integrative medicine (CIM) is a popular supportive approach among oncology patients and is on the rise worldwide. In many countries, homeopathy is being one the CIM methods integrated with a general sense that this treatment is beneficial to the well-being and quality of life (QoL) of cancer patients. In this observational study we will evaluate the feasibility of integrating homeopathic approach in patients attending the complementary and integrative oncology service at the division of oncology in Rambam Health Campus in Haifa, Israel, a major referral comprehensive cancer center.

This observational study will evaluate three main ingredients of acceptance:

* Obtaining the reasons that patients willing to integrate this supportive approach
* Patient acceptance of this supportive approach as well as compliance with the homeopathic approach
* Obtaining retrospective subjective information from the patients through validated quality of life questionnaires. (MYCaW, Distress Thermometer, and ESAS-R) Measures which are used routinely in integrative oncology encounters.

Conditions

  • Cancer
  • Quality of Life
  • Complementary Medicine
  • Integrative Medicine

Interventions

BEHAVIORAL

Feasibility of a supportive approach

Evaluating reasons for patients to use the approach

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Maria Suleymanov, RN · Rambam Health Care Campus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2028-01-01
Completion
2028-01-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833165 on ClinicalTrials.gov